Literature DB >> 11786197

Processing of neuropeptide Y, galanin, and somatostatin in the cerebrospinal fluid of patients with Alzheimer's disease and frontotemporal dementia.

C L Nilsson1, A Brinkmalm, L Minthon, K Blennow, R Ekman.   

Abstract

Alzheimer's disease (AD) and frontotemporal dementia (FTD) are two prevalent neurodegenerative disorders for which the causes are unknown, except in rare familial cases. Several changes in neuropeptide levels as measured by radioimmunoassay (RIA) have been observed in these illnesses. Somatostatin (SOM) levels in cerebrospinal fluid (CSF) are consistently decreased in AD and FTD. Neuropeptide Y (NPY) levels are decreased in AD, but normal in FTD. Galanin (GAL) levels increase with the duration of illness in AD patients. The majority of studies of neuropeptides in CSF have not been verified by HPLC. The observed decrease in a neuropeptide level as measured by RIA may therefore reflect an altered synthesis or extracellular processing, resulting in neuropeptide fragments that may or may not be detected by RIA. Matrix-assisted laser desorption time-of-flight mass spectrometry (MALDI-MS) has been shown to be a powerful technique in the analysis of biological materials without any pre-treatment, by detecting peptides and proteins at a specific mass-to-charge (m/z) ratio. We studied the processing of the neuropeptides NPY, NPY, SOM and GAL in the cerebrospinal fluid of patients with AD (n = 3), FTD (n = 3) and controls (n = 2) using MALDI-MS. We found that considerable inter-individual variability exists in the rate of neuropeptide metabolism in CSF, as well as the number of peptide fragments formed. Certain patients showed differences in the processing of specific neuropeptides, relative to other patients and controls. This analysis of the metabolic processing of neuropeptides in CSF yielded a large amount of data for each individual studied. Further studies are required to determine the changes in neuropeptide processing that can be associated with AD and FTD. With further investigations using MALDI-MS analysis, it may be possible to identify a neuropeptide fragment or processing enzyme that can be correlated to these disease states.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11786197     DOI: 10.1016/s0196-9781(01)00571-x

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  14 in total

1.  Polymorphism in neuropeptide Y influences CSF cholesterol levels but is no major risk factor of Alzheimer's disease.

Authors:  H Kölsch; D Lütjohann; F Jessen; H Urbach; K von Bergmann; W Maier; R Heun
Journal:  J Neural Transm (Vienna)       Date:  2005-06-15       Impact factor: 3.575

2.  Galanin and Neuropeptide Y Interaction Enhances Proliferation of Granule Precursor Cells and Expression of Neuroprotective Factors in the Rat Hippocampus with Consequent Augmented Spatial Memory.

Authors:  Marina Mirchandani-Duque; Miguel A Barbancho; Alexander López-Salas; Jose Erik Alvarez-Contino; Natalia García-Casares; Kjell Fuxe; Dasiel O Borroto-Escuela; Manuel Narváez
Journal:  Biomedicines       Date:  2022-06-01

3.  Co-aggregation and secondary nucleation in the life cycle of human prolactin/galanin functional amyloids.

Authors:  Debdeep Chatterjee; Reeba S Jacob; Soumik Ray; Ambuja Navalkar; Namrata Singh; Shinjinee Sengupta; Laxmikant Gadhe; Pradeep Kadu; Debalina Datta; Ajoy Paul; Sakunthala Arunima; Surabhi Mehra; Chinmai Pindi; Santosh Kumar; Praful Singru; Sanjib Senapati; Samir K Maji
Journal:  Elife       Date:  2022-03-08       Impact factor: 8.713

4.  Neuropeptide Y fragments derived from neprilysin processing are neuroprotective in a transgenic model of Alzheimer's disease.

Authors:  John B Rose; Leslie Crews; Edward Rockenstein; Anthony Adame; Michael Mante; Louis B Hersh; Fred H Gage; Brian Spencer; Rewati Potkar; Robert A Marr; Eliezer Masliah
Journal:  J Neurosci       Date:  2009-01-28       Impact factor: 6.167

5.  Somatostatin in medium-sized aspiny interneurons of striatum is responsible for their preservation in quinolinic acid and N-methyl-D-asparate-induced neurotoxicity.

Authors:  Ujendra Kumar
Journal:  J Mol Neurosci       Date:  2008-05-16       Impact factor: 3.444

6.  Specific changes of somatostatin mRNA expression in the frontal cortex and hippocampus of diabetic rats.

Authors:  Zhang XiaoMing; Zhu Xi; Shen Fang; Zhou Jilin
Journal:  J Anat       Date:  2004-03       Impact factor: 2.610

7.  Somatostatin modulates insulin-degrading-enzyme metabolism: implications for the regulation of microglia activity in AD.

Authors:  Grazia Tundo; Chiara Ciaccio; Diego Sbardella; Mariaserena Boraso; Barbara Viviani; Massimiliano Coletta; Stefano Marini
Journal:  PLoS One       Date:  2012-04-03       Impact factor: 3.240

8.  The tyrosine kinase receptor Tyro3 enhances lifespan and neuropeptide Y (Npy) neuron survival in the mouse anorexia (anx) mutation.

Authors:  Dennis Y Kim; Joanna Yu; Ryan K Mui; Rieko Niibori; Hamza Bin Taufique; Rukhsana Aslam; John W Semple; Sabine P Cordes
Journal:  Dis Model Mech       Date:  2017-01-12       Impact factor: 5.758

Review 9.  Update on the core and developing cerebrospinal fluid biomarkers for Alzheimer disease.

Authors:  Mirjana Babić; Dubravka Svob Štrac; Dorotea Mück-Šeler; Nela Pivac; Gabrijela Stanić; Patrick R Hof; Goran Simić
Journal:  Croat Med J       Date:  2014-08-28       Impact factor: 1.351

Review 10.  Neuromodulation via the Cerebrospinal Fluid: Insights from Recent in Vitro Studies.

Authors:  Andreas Bjorefeldt; Sebastian Illes; Henrik Zetterberg; Eric Hanse
Journal:  Front Neural Circuits       Date:  2018-02-05       Impact factor: 3.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.